Evercore ISI re-initiated coverage of Aura Biosciences (AURA) with an Outperform rating and $13 price target Aura uses a photosensitive payload to kill tumor cells in a handful of “underserved,” early-stage indications and early data has been “quite supportive,” the analyst tells investors. The company’s main target populations are earlier than the market is used to considering and with a safe and easy-to-give regimen, Aura could potentially open up these indications and avoid competition, the analyst added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology
- Aura Biosciences Reports Q3 2025 Financial Results
- Positive Outlook for Aura Biosciences Inc: Strong Financial Position and Promising Clinical Progress Justify Buy Rating
- Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology Expansion
- Aura Biosciences reports Q3 EPS (40c), consensus (47c)